The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer

International Journal of Cancer

Volumn 130, Issue 1, 2012, Pages 20-28

  Yamamura, Shogo ^a   Matsumura, Noriomi ^a   Mandai, Masaki ^a   Huang, Zhiqing ^b   Oura, Tomonori ^a   Baba, Tsukasa ^a   Hamanishi, Junzo ^a   Yamaguchi, Ken ^a,b   Kang, Hyun Sook ^a   Okamoto, Takako ^a   Abiko, Kaoru ^a   Mori, Seiichi ^c   Murphy, Susan K ^b   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b DUKE UNIVERSITY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

metastasis; ovarian cancer; TGF

Indexed keywords

A 83 01; ANTINEOPLASTIC AGENT; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CANCER TISSUE; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OMENTUM; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OMENTUM; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMAD2 PROTEIN; SURVIVAL RATE; THIOCARBAMATES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80255122691     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25961     Document Type: Article

References (34)

1. Roett MA, Evans P,. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16.
2. Tan DS, Agarwal R, Kaye SB,. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006; 7: 925-34. (Pubitemid 44615952)
3. Derynck R, Akhurst RJ, Balmain A,. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29. (Pubitemid 32952643)
4. Padua D, Massague J,. Roles of TGF beta in metastasis. Cell Res 2009; 19: 89-102.
5. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17: 201-12. (Pubitemid 47124417)
6. Hamanishi J, Mandai M, Matsumura N, Baba T, Yamaguchi K, Fujii S, Konishi I,. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells (Dayton, Ohio) 2010; 28: 164-73.
7. Juul SE, Beyer RP, Bammler TK, McPherson RJ, Wilkerson J, Farin FM,. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009; 65: 485-92.
8. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available at
9. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21. (Pubitemid 32397092)
10. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7. (Pubitemid 43128862)
11. Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, Potti A, Bild A, Nevins JR,. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res 2008; 68: 8525-34.
12. Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR,. Patterns of cell signaling pathway activation that characterize mammary development. Development (Cambridge, England) 2008; 135: 2403-13.
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP,. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50. (Pubitemid 41528093)
14. Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, Ohira M, Hirakawa K,. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 2008; 14: 2850-60.
15. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127-33. (Pubitemid 44803931)
16. Halder SK, Beauchamp RD, Datta PK,. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005; 7: 509-21. (Pubitemid 40791869)
17. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009; 7: 210-20.
18. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR,. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009; 28: 2796-805.
19. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K,. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002; 7: 1191-204. (Pubitemid 36024597)
20. Massague J,. TGF beta in Cancer. Cell 2008; 134: 215-30.
21. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T, Weghorst CM,. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 1998; 58: 4227-32. (Pubitemid 28450015)
22. Alvi AJ, Rader JS, Broggini M, Latif F, Maher ER,. Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. Mol Pathol 2001; 54: 240-3. (Pubitemid 32730399)
23. Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM, Chen L, Hwang JJ,. TGF beta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 2000; 18: 493-9. (Pubitemid 32844250)
24. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr., Stack MS,. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001; 80: 245-53. (Pubitemid 32158466)
25. Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T,. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005; 96: 791-800. (Pubitemid 43019830)
26. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S,. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005; 169: 801-11. (Pubitemid 41002885)
27. Vlodavsky I, Friedmann Y,. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Investig 2001; 108: 341-7. (Pubitemid 32730777)
28. Pizarro GO, Zhou XC, Koch A, Gharib M, Raval S, Bible K, Jones MB,. Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse. Int J Cancer 2007; 120: 2339-43. (Pubitemid 46642119)
29. Cheung ST, Wong SY, Leung KL, Chen X, So S, Ng IO, Fan ST,. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7629-36. (Pubitemid 39557526)
30. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL,. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005; 65: 8896-904. (Pubitemid 41377379)
31. Horita Y, Ohashi K, Mukai M, Inoue M, Mizuno K,. Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase. J Biol Chem 2008; 283: 6013-21.
32. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF,. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008; 22: 308-21. (Pubitemid 351214273)
33. Abendstein B, Stadlmann S, Knabbe C, Buck M, Muller-Holzner E, Zeimet AG, Marth C, Obrist P, Krugmann J, Offner FA,. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine 2000; 12: 1115-9. (Pubitemid 30479497)
34. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ,. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7: 829-40. (Pubitemid 351551036)